“Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study” (2023) Biomolecules and Biomedicine, 23(6), pp. 1089–1095. doi:10.17305/bb.2023.9253.